Abstract 30P
Background
Accelerated partial breast irradiation (APBI) is now widely adopted in the treatment with low risk early breast cancer worldwide. Both stereotactic body radiotherapy (SBRT) using Cyberknife (CK) and interstitial brachytherapy (IB) are available for APBI. This study was designed to compare the dosimetric characteristics of organ at risk and the clinical outcome between two different techniques.
Methods
Forty-four patients with left sided early breast cancer treated by APBI in our institute were reviewed. The radiation doses are 30Gy in 5 fractions, in 5 consecutive days using CK and 34Gy in 10 fractions, BID in 5 consecutive days using IB. Dosimetric parameters of OARs were calculated for both techniques and compared. The preliminary clinical outcomes include the local recurrence rate, acute toxicity (CTCAE V5.0) and cosmetic evaluation (Harvard scales) were analyzed.
Results
The median follow up time of CK group and IB group were 19.3 months (range: 4.5∼48.4 months) and 53.5months, respectively. Two patients from IB group had sentinel lymph node micrometastasis in the final pathology report and whole breast irradiation plus regional lymph node irradiation was added subsequently. One patient from IB group had regional lymph node recurrence during follow up and underwent surgery and re-irradiation with stable disease now. Most common acute toxicity was grade 1 radiation dermatitis. Neither radiation pneumonitis nor heart events were noted during the follow up. Multiple small scars left for more than 6 months in a few patients after interstitial brachytherapy. Patients reported cosmetic results according to Harvard scales, with “good” score in most patient of IB group and no cases described as “poor”. Dosimetric parameters of OAR showed the heartV150cGy of CK and IB was 23.5% and 59.2%. The mean heart dose of CK and IB were 117.1cGy and 215.6cGy.
Conclusions
APBI by SBRT using CK is a non-invasive procedure and has better dose-sparing effect on the heart. There were less risks of wound infection or delayed wound healing when using CK. Since no small scars left on the breast when using CK, better cosmetic outcome is expected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract